Citi analyst David Lebowitz has maintained their neutral stance on BMRN stock, giving a Hold rating today.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
David Lebowitz has given his Hold rating due to a combination of factors, primarily focusing on BioMarin Pharmaceutical’s recent performance and future prospects. The company reported strong financial results for the fourth quarter of 2024, exceeding expectations in topline revenues and non-GAAP earnings per share, largely driven by the success of its existing products such as Voxzogo and other enzyme replacement therapies.
However, while BioMarin’s guidance for 2025 suggests continued growth, particularly for Voxzogo, the rate of growth is expected to decelerate as the product nears blockbuster status. Additionally, while BioMarin’s financial projections, including a significant expansion in non-GAAP operating margins and earnings per share, are positive, the anticipated growth rate for Voxzogo is expected to slow down in the following years. These elements, coupled with the inherent risks associated with pharmaceutical investments, contribute to Lebowitz’s decision to maintain a Hold rating on the stock.
Lebowitz covers the Healthcare sector, focusing on stocks such as Exelixis, Ionis Pharmaceuticals, and PTC Therapeutics. According to TipRanks, Lebowitz has an average return of 2.3% and a 52.50% success rate on recommended stocks.